What is MediWound?
MediWound is an Israeli biopharmaceutical firm dedicated to the development, manufacturing, and commercialization of innovative therapeutics. Its core technology revolves around patented proteolytic enzymes, designed to address significant unmet needs in the treatment of severe burns, chronic wounds, and other hard-to-heal conditions. Founded in 2001, the company leverages its proprietary enzyme platform to create novel solutions for complex wound care challenges, positioning itself as a key player in the advanced wound healing market.
How much funding has MediWound raised?
MediWound has raised a total of $85.7M across 3 funding rounds:
Stock Offering
$70M
Unspecified
$9M
Other Financing Round
$6.7M
Stock Issuance/Offering (2014): $70M, investors not publicly disclosed
Unspecified (2022): $9M led by Biomedical Advanced Research and Development Authority (BARDA
Other Financing Round (2023): $6.7M supported by U.S. Department of Defense
Key Investors in MediWound
U.S. Department of Defense
The U.S. Department of Defense is the federal department responsible for coordinating and supervising all agencies and functions of the government directly related to national security and the United States Armed Forces. It manages defense policy, military operations, and oversees the development and implementation of advanced security technologies.
Biomedical Advanced Research and Development Authority (BARDA
BARDA enhances the nation's public health security and emergency preparedness by facilitating communication on innovative medical countermeasures between federal agencies and public stakeholders. The organization focuses on advanced research and development in areas such as chemical, biological, radiological, and nuclear threats, as well as vaccines and therapeutics.
What's next for MediWound?
The recent major strategic investment, particularly from entities like the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), signals a strong validation of MediWound's technology for critical applications, potentially including defense and public health security. This backing is likely to accelerate the company's clinical development pipeline, expand manufacturing capabilities, and facilitate broader market penetration. MediWound is poised to further solidify its position in the biopharmaceutical sector by capitalizing on these strategic partnerships and governmental support, driving innovation in advanced wound care solutions.
See full MediWound company page
